Andreas Michael Schmitt
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Jörger M, Alonso G, Goebeler M, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz M, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo J, Koster K, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt A, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle P, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll F, Wild P, Chun F, Reis H, Lloyd P, Machacek M, Gajewski T, Fridman W, Eggermont A, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, Dantas-Silva A, Lichtenegger F, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature 2024
Dec 11, 2024Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Dec 11, 2024Nature 2024
Melero Ignacio, de Miguel Luken Maria, de Velasco Guillermo, Garralda Elena, Martin-Liberal Juan, Jörger Markus, Alonso Guzman, Goebeler Maria-Elisabeth, Schuler Martin, König David, Dummer Reinhard, Reig Maria, Rodriguez Ruiz Maria-Esperanza, Calvo Emiliano, Esteban-Villarrubia Jorge, Oberoi Arjun, Sabat Paula, Soto-Castillo Juan José, Koster Kira-Lee, Saavedra Omar, Sayehli Cyrus Michael, Gromke Tanja, Läubli Heinz, Ramelyte Egle, Fortuny Marta, Landa-Magdalena Ana, Moreno Irene, Torres-Jiménez Javier, Hernando-Calvo Alberto, Hess Dagmar, Racca Fabricio, Richly Heike, Schmitt Andreas Michael, Eggenschwiler Corinne, Sanduzzi-Zamparelli Marco, Vilalta-Lacarra Anna, Trojan Jörg, Koch Christine, Galle Peter R, Foerster Friedrich, Trajanoski Zlatko, Hackl Hubert, Gogolla Falk, Koll Florestan J, Wild Peter J, Chun Felix Kyoung Hwan, Reis Henning, Lloyd Peter, Machacek Matthias, Gajewski Thomas F, Fridman Wolf H, Eggermont Alexander M M, Bargou Ralf C, Schöniger Sandra, Rüschoff Josef, Tereshchenko Anastasiia, Zink Carina, Dantas-Silva Amanda, Lichtenegger Felix S, Akdemir Julia, Rüdiger Manfred, L'Huillier Phil, Dutta Aradhana, Haake Markus, Auckenthaler Alexandra, Gjorgjioska Ana, Rössler Bernhard, Hermann Frank, Liebig Mara, Reichhardt Daniela, Schuberth-Wagner Christine, Wischhusen Jörg, Fettes Petra, Auer Marlene, Klar Kathrin, Leo Eugen
Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
Schmitt A, Walter M, Herbrand A, Jörger M, Moffa G, Novak U, Hemkens L, Kasenda B. Characteristics and survival of patients with cancer with intended off-label use-a cohort study. BMJ Open 2022; 12:e060453.
May 24, 2022Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
May 24, 2022BMJ Open 2022; 12:e060453
Schmitt Andreas Michael, Walter Martin A, Herbrand Amanda Katherina, Jörger Markus, Moffa Giusi, Novak Urban, Hemkens Lars G, Kasenda Benjamin
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Herbrand A, Hemkens L, Sricharoenchai S, Novak U, Mc Cord K, Jörger M, Hoogkamer A, Ewald H, Diem S, Briel M, Schmitt A, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019; 4:e000596.
Dec 1, 2019Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Dec 1, 2019ESMO Open 2019; 4:e000596
Herbrand Amanda Katherina, Hemkens Lars G, Sricharoenchai Sirintip, Novak Urban, Mc Cord Kimberly Alba, Jörger Markus, Hoogkamer Anouk, Ewald Hannah, Diem Stefan, Briel Matthias, Schmitt Andreas Michael, Kasenda Benjamin